RA
CNCE

Royce & Associates’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Royce & Associates’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,425
Closed -$21K – 1219
2018
Q3 		$21K Buy
1,425
+758
+114% +$11.9K ﹤0.01% 1150
2018
Q2 		$11K Buy
667
+344
+107% +$6.68K ﹤0.01% 1200
2018
Q1 		$7K Buy
+323
New +$7.18K ﹤0.01% 1228

Other funds holding CNCE

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royce & Associates's CNCE Position: Q4 2018 in Review

Royce & Associates sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2018, closing a stake of 1,425 shares — an estimated $21K sold.

Royce & Associates first reported a position in CNCE in Q1 2018 and held it in 3 quarters. The position peaked at $21K in Q3 2018. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2018.

  • Royce & Associates reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Royce & Associates sold 1,425 Concert Pharmaceuticals, Inc. shares in Q4 2018, an estimated $21K.
  • Royce & Associates first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • Royce & Associates's Concert Pharmaceuticals, Inc. position peaked at $21K in Q3 2018.
  • 93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2018.

Based on Royce & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.